Ropes & Gray represented AvenCell Therapeutics in the transaction, and Wilson Sonsini Goodrich & Rosati advised Novo Holdings and F-Prime Capital on the transaction. AvenCell Therapeutics...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised JP Morgan Life Sciences Private Capital on the transaction. Pathalys Pharma, Inc., a private biopharmaceutical company in the late stages...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction. Magenta Medical (Magenta) announced that it has raised $105 million in financing. The financing was...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised LENZ Therapeutics on the transaction. LENZ Therapeutics (Nasdaq: LENZ), a late clinical-stage biopharmaceutical company, announced that it has entered into...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised SR One, Norwest Venture Partners, and Delos Capital on the transaction. Zenas BioPharma, a clinical-stage global biopharmaceutical company, announced an...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction. Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, announced the close of a $103 million Series A...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised investor Novo Holdings on the transaction. Obsidian Therapeutics, Inc. (Obsidian), a clinical-stage biotechnology company, announced it closed an oversubscribed $160.5...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is advising Arcellx on the transaction. Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD) announced that they have...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction. MapLight Therapeutics announced a $225 million Series C financing co-led by Novo Holdings, 5AM Ventures, Cowen...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Novo Holdings A/S and Vida Ventures on the transaction. Avalyn Pharma Inc. announced the closing of an oversubscribed $175 million...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Forte Biosciences in the transaction. Forte Biosciences (NASDAQ: FBRX) announced key R&D updates for its product candidate FB-102 (a proprietary molecule...
You must be a Standard 1 Year member to access this content.
